Skip to Content
  • Previous Rank-
  • Revenue 3 Yr Annual Growth Rate109%
  • Revenue 3 Yr Growth Rank1
  • EPS 3 Yr Annual Growth Rate392%
  • EPS 3 Yr Growth Rank1
  • Total Return 3 Yr Annual Rate-2%
  • Total Return 3 Yr Rank97

In an era of drug development that’s produced seeming miracles like gene editing and cancer immunotherapy, the business of “injectables” may come across as quaint. But there’s nothing boring about coming up with new ways of mixing and administering therapies in a way that helps patients in novel ways. And there’s certainly nothing boring about a 36% return on shareholder investment in 2018 alone. Eagle Pharmaceuticals is a standout among its specialty pharmaceutical peers for investors, no matter how bread-and-butter its aspirations may seem.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Location
Woodcliff Lake, N.J.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak-
Years on List1
CEO
Scott Tarriff
Websitehttp://www.eagleus.com
Revenue and net income for the four quarters ended on or before April 30, 2018. Total return for the period ended June 29, 2018.

Revenue, Net Income

Revenue past four quarters ($M)$207
Net Income past four quarters ($M)$32

Growth Rates and Ranks

Revenue 3 Yr Growth Rank1
Revenue 3 Yr Annual Growth Rate109%
EPS 3 Yr Growth Rank1
EPS 3 Yr Annual Growth Rate392%
Total Return 3 Yr Rank97
Total Return 3 Yr Annual Rate-2%
Beat S&P 500 (11.9%)
no
P/E Ratio32